Introduction 63
Vancomycin (VAN) and piperacillin-tazobactam (TZP) are two of the most commonly 64
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Discussion 148
While a growing number of clinical studies have reported that VAN+TZP is associated 149 with increased rates of AKI as measured by SCr, we demonstrated that VIKI from VAN+TZP is 150 not worse than VAN alone utilizing a translational rat model and a cellular model. In fact, our rat 151 data suggest that TZP may be initially protective against VIKI. The rat data were consistent 152 among relevant urinary biomarkers (i.e. KIM-1 and clusterin) and histopathology. VAN resulted 153 in earlier damage at day 1 compared to VAN+TZP, TZP, or saline. By day 3 for urinary KIM-1 154 and clusterin, VAN+TZP was similar to VAN alone and elevated compared to TZP alone and 155 saline. On day 3 for histopathology, we observed casts in all rat drug groups, but more casts 156
were seen in the VAN and VAN+TZP groups. Categorical histopathology scores indicated VAN 157 was worse than VAN+TZP and other comparators. The NRK-52E cell line ( Figure 3b ) findings 158 also demonstrated that VAN+TZP is not worse than VAN alone. Together, these data question 159 the biologic plausibility of VAN+TZP resulting in increased kidney toxicity. To the best of our 160 knowledge, this is the first study investigating the effect of VAN+TZP on kidney injury using 161 translational models focused on histopathology and biomarkers capable of discerning direct 162 toxicity (as opposed to SCr as a surrogate). 163
Our experimental animal data are consistent with a previous study that demonstrated 164 VIKI in mice but did not identify an increased signal with TZP when using plasma urea as a 165 surrogate for AKI (36) . Notably, authors used a VAN 25 mg/day IP for 2 days [which equates to 166 roughly 1000 mg/kg/day or a human allometric scaled dose of ~80 mg/kg/day (37)] and 167 observed ATN with granular material in the tubular lumen and cast formation. Human VAN 168 doses are ~60 mg/kg/day even at the upper end of the dosing range (38). This investigation 169 also employed a very low dose of TZP at 100 mg/kg/day IP for 2 days [which is equivalent to 8.2 170 mg/kg/day human dose (37)]. A standard human dose for a 70 kg patient is ~ 190 mg/kg/day 171 (39). Thus, it was possible that the very high VAN dose and the very low dose of TZP was the 172 reason for not observing increased toxicity with VAN+TZP. In the present study, we 173 allometrically scaled VAN and TZP to the human dose and did not observe an increase in 174 nephrotoxicity with VAN+TZP (when compared to VAN alone studies have also failed to find differences in AKI rates (with SCr as a surrogate) (48, 49) . 199
Given our findings and those others, the most likely explanation for the reported increase in AKI 200 with VAN+TZP is a false-positive from an imperfect surrogate of kidney injury, i.e. serum 201
creatinine. 202
Clinical studies generally utilize either the RIFLE or the AKIN definitions to classify acute 203 kidney injury according to SCr (50) . SCr is easily measured; though, it is non-specific for kidney 204 injury because transit is defined by secretion and re-absorption (in addition to free filtration) (25) . were recently demonstrated as the most sensitive biomarkers for predicting VIKI defined by 231 histopathology (Antimicrob Agents Chemo manuscript invited revision), and 2) multiple samples 232 over time facilitate temporal investigation of toxicity after renal insult. Both of these urinary 233 biomarkers are reasonably specific for tubular toxicity, the location of VIKI (34). KIM-1 is highly 234 sensitive and specific for proximal tubule damage, the locale of VIKI (34). KIM-1 is highly 235 conserved between rats and humans, thus the predictive capacity of rat KIM-1 for VIKI is highly 236 compelling as a pre-clinical model. A human homolog, KIM-1b, is structurally similar except for 237 the cytoplasmic domain (59). Clusterin is present in kidney tubules, is anti-apoptotic, and 238 confers cell protection (60). Since it is not filtered through the glomeruli, elevation should 239 indicate tubular damage (60). 240
Several limitations exist in these data. These data are from a translational rat model, but 241 urinary biomarker and histopathological data from the rat is a well-accepted surrogate for 242 human pathobiology. By employing multiple biomarkers and histopathology, we assessed for 243 the multiple possible manifestations of VIKI. This study was able to circumvent many of the 244 limitations of current clinical data by nature of being prospective and experimental. Obtaining 245 serial urine over time further strengthens the understanding of the time course of toxicology. 246
Histopathology was elevated for all 3 groups when compared to saline; however, when 247 compared to PT, only vancomycin was elevated. This may reflect the inherent subjectivity of 248 histopathologic assessment as the control group was identified to the pathologist (per standard 249 practice (61)); however, the pathologist was blinded to treatments received. Thus, urinary 250 biomarkers may be a more unbiased assessment of AKI. We are currently limited in that that 251 creatinine values have not yet been analyzed. Creatinine will be assayed from plasma and urine 252 in future studies. Additionally, we have not yet conducted drug assays for VAN or TZP, though 253 these experiments are planned. Finally, while we saw signal for KIM-1 and clusterin in our 254 study, osteopontin did not differ, but it is also not the best biomarker for VIKI (Antimicrob Agents 255
Chemo, manuscript invited revision) and it is not specific for proximal tubule necrosis (62). 256
Finally, we constructed multiple models for our kidney biomarker data. While the constant 257 variance was violated in our repeated measures ANOVA, our mixed model analyses and our 258 LOESS regressions resulted in similar interpretations. VAN resulted in higher KIM-1 and 259 clusterin on days 1 and 2, and VAN+PTZP was not different from VAN by day 3. All models 260 agreed that VAN+PT was not worse and TZP may be protective in initial days. receive VAN 150 mg/kg/day (n=8), TZP 1400 mg/kg/day (n=8), and VAN + TZP at the same 282 doses (n=10) or normal saline (n=6). Surgeries and surgical care were carried out as previously 283 described (35). The VAN 150mg/kg/day dose was chosen based on previous studies (34, 64, 284 65) and to approximate the human dose (30 mg/kg/day) allometrically scaled for the rat (i.e. 30 285 mg/kg * 6.2 (rat factor) = 186 mg/kg) (66). The TZP 1400 mg/kg/day was chosen to approximate 286 the human dose (225 mg/kg/day) allometrically scaled for the rat (i.e. 225 mg/kg * 6.2 (rat 287 factor) = 1395 mg/kg). VAN was given IV via the left jugular catheter as this has been shown to 288 result in VIKI in our model, and TZP was given IP to extend residence time. Animals were 289 placed in metabolic cages on day -1 and from day 1 through day 3 (Figure 2a ). Rats received 290 the first dose of study drug on day 1. In addition to saline as a control, animals served as their 291 own controls, comparing each study day to pre-therapy (i.e. day -1). Rats were housed in a 292 light and temperature-controlled room for the duration of the study and allowed free access to 293 water and food, including the time in which they resided in metabolic cages (Lab Products Inc., 294 catalogue # 40618-R, Seaford, Delaware). 295
296
Blood and urine collection 297
Blood samples (0.125 mL) were drawn from a single right-sided internal jugular vein 298 catheter in a sedation-free manner when possible and were prepared as plasma (34, 35) . 
Histopathological evaluation 316
Animals were euthanized via exsanguination through the right atrium while under 317 anesthesia with ketamine/xylazine (100/10 mg/kg, by intraperitoneal injection). Kidneys were 318 then harvested, washed in cold isotonic saline. The left kidney was preserved in 10% formalin 319 solution, and the right kidney was flash frozen in liquid nitrogen for later analysis. 320
Histopathological scoring was performed by IDEXX BioAnalytics (West Sacramento, CA) on 321 paraffin-embedded hematoxylin and eosin-stained kidney sections as previously described (35). 322
In brief the PSTC Standardized Kidney Histopathology Lexicon was utilized with categorical 323 scoring according to grades from 0 to 5 (where the grades for pathological lesions were 0 for no 324 observable pathology, 1 for minimal pathology, 2 for mild pathology, 3 for moderate pathology, 4 325 for marked pathology, and 5 for severe pathology) (65, (69) (70) (71) (72) (73) . The composite score for an 326 individual animal was calculated as the highest ordinal score from any kidney site (73). 327
328
Cell culture 329
Normal rat kidney epithelial cells (NRK-52E, ATCC® CRL1571™) (74) Sigmoidal three-parameter dose response curves were generated after 48 h incubation with 347 antibiotics alone or combined with VAN at a concentration below its IC50 (i.e. with VAN 1 348 mg/mL). The relative toxicity was compared using IC50 values i.e., the drug concentration 349 resulting in 50% of maximal reduction in cell viability, obtained using GraphPad Prism version 350 7.02 (GraphPad Software Inc., La Jolla, CA). 351
352
Statistical analysis 353
For the rat studies, most statistical analyses were performed using Stata IC 15.1 (except 354 where specifically noted). Decisions to perform analyses with repeated measured ANOVA or 355 mixed models were based on the Breusch-Pagan / Cook-Weisberg test for heteroscedasticity 356 on the ANOVA model. Departure from constant variance at a P<0.05 served as a trigger to use 357 a mixed model. Urinary biomarker elevations were compared across treatment groups using a 358 mixed-effects, restricted maximal likelihood estimation regression, with repeated measures 359 occurring over days as a function of individual rat identification number. Additionally, LOESS 360 models with 95% confidence intervals were created using R version 3.5.1 (76) and the package 361 ggplot2 (77) to circumvent fit assumptions. Mild horizontal perturbation/jitter was applied to the 362 points to enhance visualization. From the mixed model, contrasts of the marginal linear 363 predictions (78) facilitated comparisons of treatment groups vs. controls of saline and pre-364 treatment values (i.e. day -1). Ordinal logistic regression was used to classify the ordered log-365 odds of being in a higher histopathologic scoring group according to treatment group. Logistic 366 regression was utilized to determine the odds of having a histopathologic score ≥2 when 367 treatment groups were compared to saline or TZP. All tests were two-tailed, with an a priori 368 level of statistical significance set at an alpha of 0.05. 369
For the in vivo studies, graphics were generated and inferential statistics were performed 370 in GraphPad Prism version 7.02 (GraphPad Software Inc., La Jolla, CA) and R 3. and day compared to baseline of saline control (Table 1a) and pre-therapy values at day= -1 (Table 1b ) 407 
